TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06571461: A Randomized, Open-label, Multi-center Phase III Clinical Study of Liposomal Irinotecan Combined With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine for Postoperative Adjuvant Treatment of Pancreatic C

Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 408 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06571461 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06571461 Rescue Dossier →